Mesa Laboratories, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2020. The request metadata references “2018 Q4,” but the supplied filing is the fiscal 2020 Form 10-K, not a 2018 quarterly filing.
Business context
Mesa Labs manufactures and markets quality-control products and services for regulated niche markets. Reportable segments were Sterilization and Disinfection Control, Instruments, Biopharmaceutical Development, and Continuous Monitoring. The Biopharmaceutical Development segment was added following the October 31, 2019 acquisition of Gyros Protein Technologies Holding AB (“GPT”). The Company exited its Cold Chain Packaging business during fiscal 2020.
The Company had 460 employees at March 31, 2020, and approximately 44% of fiscal 2020 revenue was generated outside the United States.
Key financial metrics
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $117.7 million | $103.1 million | +14% |
| Gross profit | $64.9 million | $60.9 million | +7% |
| Gross margin | 55% | 59% | Down 4 points |
| Operating income | $7.5 million | $9.8 million | -23% |
| Operating margin | 6% | 9% | Down 3 points |
| Net income | $1.3 million | $7.5 million | -82% |
| Diluted EPS | $0.31 | $1.86 | -83% |
| Operating cash flow | $26.6 million | $30.6 million | -13% |
Adjusted operating income, a non-GAAP measure excluding acquired-intangible amortization, stock compensation, and impairment charges, was $23.9 million versus $25.9 million in fiscal 2019. The filing does not provide a comparable adjusted net income measure.
Liquidity, debt, and capital allocation
- Cash and cash equivalents were $81.4 million at March 31, 2020, compared with $10.2 million a year earlier.
- Working capital increased to $96.8 million from $10.0 million.
- The Company issued $172.5 million principal amount of 1.375% convertible senior notes due August 15, 2025, receiving net proceeds of approximately $167.1 million.
- The Company issued 431,250 common shares for net proceeds of approximately $85.0 million.
- Proceeds funded the GPT acquisition, which required adjusted cash consideration of $181.5 million, and provided funds for acquisitions and general corporate purposes.
- The prior term loan and revolving credit facility were repaid or terminated. Net carrying value of the convertible notes was $140.3 million at year-end; principal repayment is due in 2025 unless earlier converted or repurchased.
- Quarterly dividends remained $0.16 per share, or $0.64 per share for the year. No shares were repurchased during fiscal 2020.
Segment performance and material changes
| Segment | FY2020 revenue | FY2019 revenue | FY2020 gross margin |
|---|---|---|---|
| Sterilization and Disinfection Control | $49.7 million | $46.3 million | 72% |
| Instruments | $38.0 million | $36.1 million | 64% |
| Biopharmaceutical Development | $13.9 million | Not applicable | 3% |
| Continuous Monitoring | $13.7 million | $13.8 million | 30% |
| Corporate and Other | $2.5 million | $6.9 million | 17% |
- Excluding Cold Chain Packaging, total revenue increased 20%, organic revenue growth was 2%, and gross profit increased 7%.
- Sterilization and Disinfection Control benefited from higher volumes, new customers, modest pricing, operational efficiencies, and COVID-19-related demand. Its gross margin increased from 69% to 72%.
- Instruments revenue benefited from the IBP Medical acquisition but organic revenue declined 1%, primarily because customers reduced discretionary capital spending late in the year.
- GPT contributed approximately $13.8 million of revenue and a $7.4 million net loss from November 1, 2019 through March 31, 2020. GPT gross margin was heavily reduced by $8.5 million of purchase-accounting inventory step-up amortization; excluding that charge, reported gross margin would have been approximately 64%.
- Continuous Monitoring revenue declined 1%, while gross margin fell from 40% to 30% because of lower service volumes, continued technician costs, and higher hardware prices. Management reorganized the business after year-end.
- Corporate and Other revenue declined as Cold Chain Packaging was liquidated. The Company recorded approximately $0.3 million of impairment charges and $0.05 million of exit costs in fiscal 2020. No further exit costs were expected.
Cash flow and unusual items
- Net cash used in investing activities was $185.6 million, primarily reflecting the GPT and IBP acquisitions.
- Net cash provided by financing activities was $231.3 million, driven by the convertible notes and equity offering, partially offset by debt repayments and dividends.
- Operating expenses increased 12% to $57.4 million, including higher GPT selling, administrative, research and development, acquisition-related, stock-compensation, and amortization costs.
- Amortization of acquired intangible assets was $10.6 million, stock-based compensation was $5.5 million, and GPT inventory step-up amortization was $8.5 million.
- Fiscal 2019 included a $3.3 million legal settlement and $4.8 million of impairment charges; fiscal 2020 included only $0.05 million of legal settlement expense and approximately $0.3 million of impairment expense.
- The effective tax rate was 61% in fiscal 2020, compared with 13% in fiscal 2019, due primarily to nondeductible acquired-intangible amortization, foreign tax-rate differences, valuation allowance changes, and other tax items. Management expected a normalized rate of approximately 26%, subject to share-based compensation effects.
Outlook, risks, and contingencies
Management stated that COVID-19 adversely affected Instruments, Biopharmaceutical Development, and Continuous Monitoring through delayed deliveries, reduced customer-site access, canceled conferences, lower sales leads, and reduced discretionary spending. Sterilization and Disinfection Control remained comparatively resilient because its products are consumable, regulatory-driven, and critical to healthcare operations. Management expected COVID-19 restrictions to continue negatively affecting fiscal 2021 results but could not quantify the impact.
- The Company believed available cash and liquidity were sufficient to continue operations, while reducing travel, freezing wage increases, limiting hiring, and pursuing supplier contingency plans.
- Backlog was approximately $10.1 million at March 31, 2020, versus $8.3 million a year earlier.
- GPT integration, acquisition accounting, goodwill and intangible-asset impairment, foreign currency exposure, supply-chain interruptions, regulatory compliance, cybersecurity, and customer capital-spending decisions are significant risks.
- Goodwill and other intangible assets totaled $261.4 million at year-end. The Company concluded that goodwill in continuing reporting units was not impaired, but additional impairment charges remain possible.
- The Company estimated that a hypothetical 10% strengthening of the U.S. dollar would reduce annual after-tax net earnings by approximately $3.3 million.
- IBP contingent consideration could range from zero to $0.49 million; management expected payment of approximately $0.49 million during fiscal 2021.
- Auditors issued an unqualified opinion on the financial statements but an adverse opinion on internal control over financial reporting. A material weakness involved ineffective information-technology general controls over user access and program-change management. Management expected remediation before March 31, 2021, but the weakness had not been remediated as of the filing date.
Investor verification priorities
- Verify the post-acquisition performance, integration progress, and final purchase-price allocation for GPT.
- Assess whether COVID-19-related demand declines and customer-site restrictions persisted beyond the filing date, particularly in Instruments, Biopharmaceutical Development, and Continuous Monitoring.
- Monitor gross-margin recovery after GPT inventory step-up amortization and Continuous Monitoring’s reorganization.
- Evaluate liquidity relative to the $172.5 million convertible-note principal due in 2025, including potential conversion or repurchase obligations.
- Confirm remediation and auditor reassessment of the material weakness in IT general controls.
- Review goodwill and intangible-asset impairment sensitivity, especially given the substantial acquisition-related balances and uncertain economic outlook.
- Reconcile GAAP operating income and EPS with management’s adjusted operating-income presentation and assess the recurring nature of excluded costs.